Skip to main content
PRAX
NASDAQ Life Sciences

Praxis Sets $20B+ Peak Sales Target, Discloses Launch Pricing and Two PDUFA Dates

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$324.76
Mkt Cap
$9.078B
52W Low
$160.11
52W High
$392.7
52W Position info
103% above low
Off High info
17% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

PRAX has more than doubled off its 52-week low of $160.11.

Summary

Praxis used its Investor Day to disclose launch pricing for its two lead drugs and guide to more than $20B in combined peak sales, with FDA decisions on relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027) now weeks away.


Key Events · Product Development and Regulatory · PRAX

  • Investor Day Lays Out $20B+ Peak Sales

    Management guided to more than $20B in combined peak sales: ulixacaltamide $10.0B, relutrigine $5.0B, vormatrigine $4.0B and elsunersen $1.0B.

  • Launch Pricing Corridors Disclosed

    Ulixacaltamide is planned at $50K-$100K WAC per year in essential tremor and relutrigine at $400K-$600K WAC per year in SCN2A/SCN8A DEEs, benchmarked to in-market analogs.

  • Two PDUFA Dates Weeks Away

    Relutrigine has a PDUFA date of December 27, 2026 and ulixacaltamide January 29, 2027; both launches are planned with field teams already hired and supply secured.

  • FDA Sensitivity Analyses Consistent

    Sensitivity analyses of the Essential3 primary endpoint requested by FDA during NDA review were consistent with the primary result, including a baseline-observation-carried-forward analysis at 1.41 points (p=0.0019).


Analysis · PRAX · Life Sciences

At its Investor Day, Praxis put hard numbers on the commercial story for the first time: ulixacaltamide priced at $50K-$100K WAC per year in essential tremor and relutrigine at $400K-$600K per year in SCN2A/SCN8A DEEs, with combined peak sales guidance above $20B. Two near-term FDA decisions anchor the thesis — relutrigine on December 27, 2026 and ulixacaltamide on January 29, 2027 — so the next six weeks carry binary approval risk. The company also disclosed that FDA-requested sensitivity analyses of the Essential3 primary endpoint were consistent with the primary result, which removes a key review overhang. Against a $9.1B market cap, the guidance implies substantial upside if both labels clear, but the stock now trades on execution of two launches rather than pipeline optionality.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRAX was trading at $324.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $160.11 to $392.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRAX - Latest Insights

PRAX
Nov 09, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $270.00
Real-time Price: $324.76 info
Change: +$54.76 (+20%) info
Market Cap: $9.078B info
PRAX
Nov 09, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $270.00
Real-time Price: $324.76 info
Change: +$54.76 (+20%) info
Market Cap: $9.078B info
PRAX
Aug 06, 2026, 8:32 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $337.00
Real-time Price: $324.76 info
Change: -$12.24 (-4%) info
Market Cap: $9.078B info
PRAX
Aug 06, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $337.10
Real-time Price: $324.76 info
Change: -$12.34 (-4%) info
Market Cap: $9.078B info
PRAX
Jul 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $330.00
Real-time Price: $324.76 info
Change: -$5.24 (-2%) info
Market Cap: $9.078B info